This ASX fund manager is predicting big things for biotech shares

This ASX fund manager is bullish on biotech shares…

medical imaging doctor amid images of human brains

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Platinum Asset Management Ltd (ASX: PTM) has long been one of the most followed funds management businesses on the ASX. Platinum was founded by the legendary ASX investor Kerr Neilson in the 1990s.

Ever since, the company has been a beacon of value investing on the ASX, even after Neilson's departure in 2018. Now, Platinum is headed by its co-founder and Neilson protege Andrew Clifford.

Clifford recently sat down with Livewire for an interview. It makes for some interesting reading.

Discussing both Platinum's history, and its prediction for the winning investing themes of the future, Clifford shared three insights.

Firstly, he sees a very bright and potentially lucrative shift towards the widespread adoption of electric vehicles. Platinum identifies the Korean company LG Chem as a major play in this space. Mr Clifford calls the company "one of the world's leading suppliers of batteries".

Secondly, Clifford identifies an opportunity in the search for replacements for single-use plastics. Pointing to Finnish forestry company UPM Kymmene Oy, he says he is excited about this company's plans to turn timber products into bio-plastics.

Biotech shares for the future

But, thirdly, Clifford is looking to the biotech space for potential future gains. He predicts biotech will "kickstart a revolution in healthcare. Not only in the way we define and treat diseases but also in the way we manufacture products":

The speed at which we're coming up with potential solutions in the biotech world — whether it's gene editing or mRNA — there are vast amounts of development in different areas of the sector that I think will transform the healthcare landscape…

The great lesson of the last year was obviously the way that mRNA technology could be used to create vaccines. We had investments in both BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) well ahead of COVID-19 and certainly stepped those up because we knew there would be an opportunity.

Clifford told Livewire that Dr Bianca Ogden, Platinum's International Health Care fund manager, frequently points out how "molecular biology and computer science are converging" with Artificial Intelligence (AI).

In the report, Clifford said Odgen "believes that in the next 10 years we will start defining neurological disorders by their molecular profile akin to what we do in oncology".

Exciting stuff.

The Motley Fool recently looked at some of the ASX's best-performing biotech shares over the 2021 financial year so make sure to check those out next.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Oil industry worker climbing up metal construction and smiling.
Energy Shares

ASX 200 energy shares lead the market as US trade deals fuel optimism

ASX energy shares lifted 3.94% as more US trade deals led to improved market sentiment.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

These ASX 200 shares could rise 50% to 60%

Brokers believe these shares could deliver big returns for investors.

Read more »

A girl is handed an oversized ice cream cone with lots of different flavours.
Best Shares

8 ASX All Ords shares that tripled in value in FY25

Just 8 out of the 500 companies making up the ASX All Ords achieved share price growth of 200% or…

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Woman with a scared look has hands on her face.
Broker Notes

Bapcor shares fell more than 30% yesterday. Should investors buy in the dip?

Is this a value opportunity?

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Broker Notes

Broker raises price targets on 2 ASX 200 shares to buy

Ord Minnett has just upped its 12-month share price targets on 2 buy-rated ASX 200 stocks.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »